On Demand 2025 Monday General Sessions

This course includes the following sessions from Monday's program:

  • Plenary: Drug Allergies Demystified: Practical Approaches for Accurate Diagnosis and Management
  • Dermatology Potpourri
  • Immunotherapy in the Era of Biologics
  • Navigating Complex Atopy Across the Lifespan: From Infancy to Young Adulthood
  • Creative Solutions for Addressing Asthma Management in Different Settings
  • Inborn Errors of Immunity - Updates from the Newest Parameter
  • Role of AI in Allergy Care

Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 9.0 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Target Audience

Medical professionals who treat patients with allergic and/or immunological conditions:

  • Practicing allergist/immunologists
  • Allergy/immunology Fellows-in-Training
  • Physician assistants
  • Nurses and advanced practice nurses
  • Allied health professionals
  • Primary care physicians
  • Other medical professionals

Learning Objectives

Upon completion of this session, participants should be able to:

  • Review the key steps in evaluating drug allergies in the office setting, including effective patient history-taking, diagnostic testing (such as skin tests and drug provocation tests), and strategies to integrate these evaluations into daily practice to optimize patient care.
  • Discuss the spectrum of delayed hypersensitivity reactions (SCAR and non-SCAR) and identify emerging treatment options with a focus on when and how to apply these therapies in clinical practice.
  • Explain the mechanisms and clinical management of adverse reactions to biologics and monoclonal antibodies and identify best practices for patient monitoring and risk management to improve outcomes in patients receiving these therapies.
  • Differentiate disorders that may be confused with urticaria.
  • Identify the most common causes of occupational irritant and allergic contact dermatitis and how to treat them.
  • Discover what is new in diagnosing and treating angioedema(can be hereditary and non-hereditary angioedema).
  • Assess available management options after failed primary prevention for food allergy.
  • Examine the use of food allergy therapies in school-age children, including risks, benefits and patient-related outcomes.
  • Select management options for food allergic young adults preparing for college.
  • Identify and implement key components of effective school-based asthma programs to reduce disparities, including strategies for care coordination, asthma education, and environmental trigger management.
  • Evaluate and advocate for school-based asthma policies that align with current clinical guidelines and promote equitable access to asthma care and resources within educational settings.
  • Design and/or support community-driven asthma programs that address culturally specific barriers and leverage local partnerships to improve asthma outcomes in minority populations. Collaborate effectively with community health workers and environmental remediation programs to identify and reduce home-based asthma triggers and improve patient self-management and outcomes.
  • Summarize the role of genetic testing in patients with inborn errors of immunity.
  • Deduce common non-infectious manifestations in patients with an inborn error of immunity.
  • Specify new and emerging precision therapies to consider in patients with inborn errors of immunity.
  • Understand the current AI landscape and use in Allergy care today.
  • Leverage AI to make workflows more efficient, saving time and optimizing staff.
  • Utilize AI to maximize reimbursement. Assess how AI is being used in educating students, residents, fellows, and staff.
     
Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. The ACCME defines a “ineligible company” as companies whose primary business is producing, marketing, selling, re-selling, or distributing health care goods or services, used by or on patients. Examples of such organizations include: 
 
•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers
  
The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.
Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.
Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All identified relevant financial relationships have been mitigated.

Course summary
Available credit: 
  • 9.00 AMA PRA Category 1 Credit™
  • 9.00 Attendance
  • 9.00 CBRN
Course opens: 
11/24/2025
Course expires: 
12/07/2028
Part of: 
On Demand ACAAI 2025 Annual Scientific Meeting
Rating: 
0

Allison C. Ramsey, MD, FACAAI
Jason Trubiano, PhD
Mariana C. Castells, MD, PhD, FACAAI
Rohit K. Katial, MD, FACAAI
Kelly M. Maples, MD, FACAAI
Karin A. Pacheco, MD, MSPH
Timothy J. Craig, DO, FACAAI 
Maureen M. Petersen, MD, FACAAI
Brian P. Vickery, MD
John J. Oppenheimer, MD, FACAAI
Michael Pistiner, MD, MMSc, FACAAI
Antonella Cianferoni, MD, PhD, FACAAI
J. Andrew Bird, MD, FACAAI
Akilah Jefferson, MD, MSc
Andrea A. Pappalardo Wlochowicz, MD, FACAAI
Ashley A Lowe, PhD, MSPH
Mary E. Crocker, MD, MPH
Ivan K. Chinn, MD
Benjamin Prince, MD, FACAAI
Jennifer R. Heimall, MD, FACAAI
Jay M. Portnoy, MD, FACAAI
Fatima S. Khan, MD, FACAAI
Sakina S. Bajowala, MD
Sofija D. Volertas, MD

Available Credit

  • 9.00 AMA PRA Category 1 Credit™
  • 9.00 Attendance
  • 9.00 CBRN
Please login or create an account to take this course.